PsyRx: How real the patent moat is before first human data
PsyRx’s broad patent application around ibogaine combined with antidepressants looks, at first glance, like a meaningful moat. As of year-end 2025, though, it rests much more on legal priority than on clinical proof, and the company itself says South Africa is non-substantive while the Yissum-linked work ended without a patent filing.
What This Follow-up Is Isolating
The main article argued that PsyRx’s real test is not whether it can complete a merger shell cleanup or raise another financing bridge, but whether it can get to the first human data point. This continuation isolates the IP layer inside that thesis: how much of the current story is already a real moat, and how much is still a placeholder waiting for proof.
The short answer is sharp. There is a patent application here, but not yet a proven moat. The company does hold a broad patent family around combining ibogaine or one of its derivatives with one or more antidepressants for psychiatric disorders, but nearly every meaningful route is still pending. The annual report adds two heavy qualifications of its own: in South Africa the grant is automatic rather than substantive, and the application was filed without supporting experimental results.
That is a material distinction. Before first human data, PsyRx’s IP story looks more like an early legal claim on a broad idea and less like exclusivity already anchored in a specific combination with demonstrated clinical advantage. That is not worthless. It is also not the same thing as a moat that is already closed.
What Actually Exists Today
The annual report lists two patent families. The first is a PCT-stage family around psilocybin plus another substance for bowel diseases, and the company explicitly says it does not intend to advance that family into the national phase. For the current depression thesis, that family adds very little practical moat.
The second family is what makes the headline sound stronger. It is framed very broadly around combining ibogaine or a derivative with one or more antidepressants so the combination treats some psychiatric disorder. The drafting is wide on purpose. It tries to stake out as much ground as possible.
But this is exactly where analytical discipline matters. Breadth in an application is not breadth in protection. In the company’s own table, most jurisdictions still show as pending, and the only line marked as granted is South Africa. Right after that, the company explains that the South African grant is automatic and not substantively examined. So the only formally granted line is not evidence that a substantive examiner has already endorsed the core invention.
| IP layer | What exists today | What it does provide | What it does not yet provide |
|---|---|---|---|
| Psilocybin family for bowel disease | PCT application, with no intention to enter national phase | Shows some prior filing history | Adds very little to the ibogaine-depression thesis |
| Ibogaine plus antidepressants family | Broad application across several routes, South Africa granted, most other routes pending | Legal priority and an early claim to being first | Not yet broad, substantively tested exclusivity |
| Yissum research agreement | Joint ownership in research results and an exclusive commercial license | Contractual access to any resulting technology | No filed or granted patent by itself |
Where the Protection Is Still Thin
The filing does not leave much room for illusion here. It explains that when a patent claims a combination of two or more substances, the applicant will typically need to show an unexpected result. The company itself gives examples of what that could mean: synergy, earlier onset of activity, fewer side effects, lower dosing, or an advantage in specific sub-populations.
Then comes the key sentence. The patent application was filed without supporting experimental results, and in order to obtain broad and meaningful approval the company says it will need to complete many more studies, including human studies, demonstrating clear synergistic value and positive results in specific combinations of ibogaine and other antidepressants.
That is the core point. Right now PsyRx is trying to protect a broad concept before it has shown which combination actually works better than the alternatives. So the current layer of protection looks more like a way to stop others from filing the same concept in parallel, and less like an already proven ability to keep competition away from a clinically defined, data-backed regimen.
The report even points to the future direction. A specific combination that proves superior to another combination would materially increase the chance of receiving a patent in the company’s field. In other words, even on the company’s own framing, the real moat will probably not sit around the broad phrase “ibogaine plus an antidepressant.” It will sit around a particular pairing, a particular profile, and a particular clinical result.
Yissum Adds Rights, Not a Filed Moat
Another source of confusion comes from the Yissum research agreement. On paper, it looks like an extra IP layer: PsyRx funded research in ibogaine and psilocybin, the results are jointly owned, and the company received an exclusive license, transferable and sublicensable, for commercial use of any technology developed under that work.
But here too, the filing cuts through the headline. The agreement says the company would bear patent-registration costs and pursue filings in Israel or the US, then a PCT filing, and later national-phase filings in at least three countries. Yet both the business section and note 15 add the crucial clarification: by the end of the project no patent application had been filed for the Yissum-based research, and therefore the company had no patent-registration expenses in that context.
So the Yissum agreement gives PsyRx contractual optionality and access to research output, but as of year-end 2025 it does not add a filed patent layer that strengthens the moat. More than that, the royalty framework itself explicitly contemplates a product without patent protection in the US or Europe, because the royalty rate is cut by 50% in that case, subject to a patent application having been filed and not approved. That is another clue that the commercial framework itself does not assume patent protection is already secured.
What Has to Happen for the Moat to Become Real
This is where the IP story connects directly back to the clinical thesis. PsyRx says it has already completed a preclinical safety study, an efficacy study, an ibogaine manufacturing process, and a risk-management plan, and that it is preparing for a first-in-human trial in Israel that is expected, according to the report, during 2026. It also says it plans to invest roughly NIS 2 million over the next twelve months, mainly in human clinical research and in animal efficacy work.
That matters not only for the regulatory path. It matters because this is where the proof the patent still lacks is supposed to come from. If the first human study and the work that follows show that a defined ibogaine-plus-SSRI combination produces faster response, better safety, or a more efficient dose, the patent story changes materially. If not, the headline remains broader than the protection.
In today’s terms, PsyRx mainly has the right to argue that it filed early. In next-stage terms, it still has to prove which combination actually deserves strong protection. Those are very different states, and a market that reads “patent” as if it already means a closed moat can miss the gap.
Bottom Line
PsyRx’s patent moat before first human data exists, but it is narrower than the headline can imply. There is a broad filing, there is legal priority, and there is a contractual rights layer through Yissum. Against that stand three facts that reduce the moat’s present strength: most meaningful routes have not yet been substantively tested, South Africa is not a substantive approval, and the Yissum-linked research did not become a patent filing.
So the right reading is not that PsyRx has no IP. It is that its IP still lives more in the promise phase than in the proof phase. For a pre-revenue biotech, that is a large distinction. It determines whether the story should be read as emerging exclusivity, or mainly as a legal option waiting for the science to identify the right combination.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.